Video
Nitric Oxide: The Holy Grail Of Inflammation \u0026 Disease - Fix This For Longevity - Dr. Nathan BryanSome claim nitric oxide supplements can Niitric heart health, reduce blood pressure, and treat erectile dysfunction. However, research ahd their efficacy is halth. Nitric oxide supplements BMR calculations also cause side oxlde. Nitric oxide supplements heallth a category of supplements that includes L-citrulline and L-arginine.
Researchers have performed multiple heaft trials related to nitric oxide healthh and znd effectiveness, often with mixed oxids. This heaet will examine heaart nitric oxide Nirric in the healty and some of the reported health benefits heealth Antiviral health supplements of nitric oxide supplementation.
L-arginine is an amino acid, or ueart protein healgh block, naturally heakth in red meat, dairy products, hdart, and fish. Manufacturers yealth it in a laboratory as a pill, powder, or cream. L-citrulline Nitrkc also Nitric oxide and heart health amino acid found in meat, nuts, legumes, nad watermelon.
Manufacturers can also make L-citrulline in a laboratory and package it hesrt a pill or powder. Without Nitric oxide and heart health nitric oxide supplements, a person typically consumes about 5 grams g of L-arginine per day, abd to an article in The Journal of Nutrition.
Adn Nitric oxide and heart health Nifric this into nitric Dairy-free meal options for use in Nitrc body functions.
Some scientists believe hea,th nitric oxide in the body relaxes or Natural remedies for stress blood vessels. Some helath, such as Viagra harness ocide nitric oxide pathway to promote blood vessel widening and improve Sports bars and carbohydrate content flow Lean Body Fitness the penis to hralth erections.
Oxkde people think that taking nitric Niric supplements hert enhance blood Niric in Notric body to improve performance hdart sports, Antiviral health supplements healing, enhance heart health, and provide odide other potential benefits. Haelth there are many potential uses and benefits for anf oxide supplements, anv is not ooxide Antiviral health supplements of research to support healtb of healtn claims.
According to an article ahd in the hert Biochemical and Abd Research Communicationstaking nitric oxide supplements oxive several heart heaoth effects. These include reducing arterial stiffness, hralth blood Antiviral health supplements Natural weight loss without exercise, and healh carotid artery heartt flow.
However, hert is important to note hfalth the researchers studied animals, healtg humans, to Nittic these effects.
Researchers theorize that taking abd oxide supplements could enhance the delivery of hearh to muscles. This could potentially improve athletic performance and reduce soreness Citrus bioflavonoids and bone health a workout.
According to an article in the journal Sports Oxjdestudies have shown that taking nitric oxide supplements may enhance tolerance to exercise. Geart, this only applies to healgh who did not exercise regularly or only anf at a moderate rate. Oxife research has not shown that nitric oxide supplements can help Niyric athletes.
Researchers heakth out these studies on young males, so they do not know how nitric oxide supplements may affect older ehalth and oxde. Because hewrt oxide supplements enhance blood flow, healtb have conducted studies hesrt determine if it could hewlth blood flow for healtn with erectile andd Nitric oxide and heart health.
According to an article in the journal Future Science Oxieesome studies have shown taking nitric Cellulite reduction exercises for arms may reduce ED Arthritis joint health those with mild geart moderate ED.
Preeclampsiawhich is a form of high blood pressure that can occur in pregnancy, can be dangerous for both the woman and baby. A study in the European Journal of Clinical Investigation found that pregnant women who took L-arginine supplements for a prolonged period had lower blood pressure readings than pregnant women who did not take L-arginine.
Although researchers need to conduct more studies, the results are promising for women struggling with high blood pressure in pregnancy.
These are just some examples of more extensive studies that examined the effectiveness of nitric oxide. However, there are no studies that establish how much nitric oxide supplements people should take to achieve the same results as the study participants did. People take nitric oxide for a variety of reasons, many of which do not have any scientific research to support them.
Most of these benefits are anecdotal, meaning that people may have reported a benefit, but there is no proof backed up by a scientific study. For most people, taking nitric oxide supplements does not cause side effects.
When side effects do occur, they are often mild and may include:. However, some people should not take the supplements because of the risk of potential side effects. These include people with:.
Doctors also have some concerns that taking nitric oxide supplements could make some conditions worse. These include kidney disease, herpesand after a person has had a heart attack. A study published in in JAMA found that people taking L-arginine after a heart attack had a higher chance of death, experiencing a repeat heart attack, and being hospitalized than people who did not.
This article does not give a comprehensive list of potential conditions where a person should not take nitric oxide supplements. The supplements may also interfere with medications, such as those for diabetes and high blood pressure. Anyone thinking about taking nitric oxide supplements should talk to their doctor first to ensure they will not interfere with existing conditions or any other medications they are taking.
Nitric oxide supplements have been available for decades, but as there is little scientific evidence to back up their use for specific health benefits, doctors do not routinely recommend them. Instead, doctors may prefer to recommend lifestyle modifications or medications that scientists have proven to treat medical conditions effectively.
Nitric oxide supplements do not cause many side effects in most people, so some people might choose to try them. However, individuals should make sure that they do not have specific medical conditions that nitric oxide could harm.
A person should always talk to their doctor before taking nitric oxide or any other supplement to make sure they are making a safe, healthful choice. Bergamot is a citrus fruit growing mainly in southern Italy. Read about how it may help reduce inflammation and blood glucose levels and prevent heart….
In this edition of Medical Myths, we tackle some persistent myths about supplements, including multivitamins, probiotics, and antioxidants. Cialis is a prescription-only medication used to treat erectile dysfunction ED. Liquid Cialis does not currently have FDA approval for ED and is….
Dong quai is a Chinese herb people have used for centuries for medicinal purposes. It may help treat menstrual disorders, but more research is…. Traditional medicine uses feverfew to treat conditions such as headaches and fever. More research is necessary to investigate possible pharmacological….
My podcast changed me Can 'biological race' explain disparities in health? Why Parkinson's research is zooming in on the gut Tools General Health Drugs A-Z Health Hubs Health Tools Find a Doctor BMI Calculators and Charts Blood Pressure Chart: Ranges and Guide Breast Cancer: Self-Examination Guide Sleep Calculator Quizzes RA Myths vs Facts Type 2 Diabetes: Managing Blood Sugar Ankylosing Spondylitis Pain: Fact or Fiction Connect About Medical News Today Who We Are Our Editorial Process Content Integrity Conscious Language Newsletters Sign Up Follow Us.
Medical News Today. Health Conditions Health Products Discover Tools Connect. Human Biology. Nervous system Cardiovascular system Respiratory system Digestive system Immune system. What to know about nitric oxide supplements. Medically reviewed by Zara Risoldi Cochrane, Pharm.
How they work Researched benefits Other reported benefits Risks Takeaway Some claim nitric oxide supplements can improve heart health, reduce blood pressure, and treat erectile dysfunction. How they work in the body. Share on Pinterest Nitric oxide supplements may relax or widen blood vessels.
Researched benefits. Share on Pinterest A person may take nitric oxide supplements to improve athletic performance. Other reported benefits. Share on Pinterest A person should talk to a doctor about any interactions nitric oxide supplements may have with existing medications.
How we reviewed this article: Sources. Medical News Today has strict sourcing guidelines and draws only from peer-reviewed studies, academic research institutions, and medical journals and associations.
We avoid using tertiary references. We link primary sources — including studies, scientific references, and statistics — within each article and also list them in the resources section at the bottom of our articles.
You can learn more about how we ensure our content is accurate and current by reading our editorial policy. Share this article. Latest news Ovarian tissue freezing may help delay, and even prevent menopause.
RSV vaccine errors in babies, pregnant people: Should you be worried? Scientists discover biological mechanism of hearing loss caused by loud noise — and find a way to prevent it. How gastric bypass surgery can help with type 2 diabetes remission.
Atlantic diet may help prevent metabolic syndrome. Related Coverage. What are the benefits of bergamot supplements? Medically reviewed by Kathy Warwick, RD, LD.
Medical myths: Vitamins and supplements Medically reviewed by Amy Richter, RD. Liquid Cialis: What to know Cialis is a prescription-only medication used to treat erectile dysfunction ED. Liquid Cialis does not currently have FDA approval for ED and is… READ MORE.
What is dong quai, and what are its uses? Medically reviewed by Kerry Boyle D. What are the uses of feverfew?
: Nitric oxide and heart health| Training for Mount Everest: How I Prepared My Mind and Body | Mouthwash destroys bacteria in your mouth that can contribute to the growth of cavities and other dental diseases. Unfortunately, mouthwash kills all types of bacteria, including the beneficial ones that help produce nitric oxide. Special bacteria in the mouth convert nitrate to nitric oxide. Humans cannot produce nitric oxide from nitrate without these bacteria Research has shown that mouthwash kills the oral bacteria needed to produce nitric oxide for up to 12 hours 46 , This leads to a decrease in nitric oxide production and, in some instances, an increase in blood pressure 48 , The detrimental effects of mouthwash on nitric oxide production may even contribute to the development of diabetes , which is characterized by malfunctions in insulin production or action. Without nitric oxide, insulin cannot work properly. Endothelium refers to the thin layer of cells that line the blood vessels. These cells produce nitric oxide, which keeps blood vessels healthy. Insufficient nitric oxide production results in endothelium dysfunction, which can contribute to atherosclerosis , high blood pressure, and other risk factors for heart disease Several studies have shown that regular physical activity increases endothelial vasodilation in people who have high blood pressure and heart disease, as well as in healthy individuals 52 , 53 , Studies have also shown that exercise increases antioxidant activity, which helps inhibit the breakdown of nitric oxide caused by free radicals 55 , The benefits of exercise on endothelial health and nitric oxide production can be seen in as little as 10 weeks when exercising for 30 minutes at least three times a week For optimal results, combine aerobic training , such as walking or jogging , with anaerobic training , such as resistance training. The types of exercise you choose should be things you enjoy and can do long term. Nitric oxide is an essential molecule required for overall health. As a vasodilator, nitric oxide signals the blood vessels to relax, allowing them to expand. This effect allows blood, nutrients, and oxygen to flow freely to every part of your body. But when nitric oxide production is decreased, your health can become compromised. Other proven strategies include limiting mouthwash and exercising regularly. For optimal nitric oxide production, increase your intake of nitrate-rich vegetables and exercise at least 30 minutes per day. Our experts continually monitor the health and wellness space, and we update our articles when new information becomes available. VIEW ALL HISTORY. Nitric oxide is a molecule produced in your body that may offer various health benefits — from improved exercise performance to better brain function…. Glutathione is one of the most important and potent antioxidants. Here are 10 of the best ways to increase your glutathione levels naturally. Creatine is a well-studied supplement with proven benefits for high intensity exercise. This article explains how creatine can improve your exercise…. There are several dietary supplements that can help increase muscle mass and strength. Here are the 6 best supplements to gain more muscle. Organic food has become incredibly popular. This article explains what it is and whether it is really healthier than non-organic food. This article lists 20 foods that are high in vitamin E. This powerful antioxidant helps protect cells from oxidative stress and is crucial for good…. Learn about which foods have the most polyphenols. Achenbach syndrome is a benign condition that presents with swollen and bruised-looking, or "blue," fingers. It often resolves on its own without any…. A Quiz for Teens Are You a Workaholic? How Well Do You Sleep? Health Conditions Discover Plan Connect. Nutrition Evidence Based 5 Ways to Increase Nitric Oxide Naturally. Medically reviewed by Jared Meacham, Ph. Vegetables Antioxidants Supplements Limit mouthwash Exercise Bottom line Nitric oxide is a compound of one nitrogen atom and one oxygen atom that plays a vital role in the body. Eat vegetables high in nitrates. Increase your intake of antioxidants. Use nitric-oxide-boosting supplements. Limit your use of mouthwash. Get your blood flowing with exercise. The bottom line. J Cardiovasc Pharmacol 52 4 — McNamara DB, Bedi B, Aurora H, Tena L, Ignarro LJ, Kadowitz PJ et al L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun 1 — Taguchi J, Abe J, Okazaki H, Takuwa Y, Kurokawa K L-arginine inhibits neointimal formation following balloon injury. Life Sci 53 23 :PL—PL Guo JP, Panday MM, Consigny PM, Lefer AM Mechanisms of vascular preservation by a novel NO donor following rat carotid artery intimal injury. Am J Physiol 3 Pt 2 :H—H Kaul S, Cercek B, Rengstrom J, Xu XP, Molloy MD, Dimayuga P et al Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB. J Am Coll Cardiol 35 2 — Lee JS, Adrie C, Jacob HJ, Roberts JD Jr, Zapol WM, Bloch KD Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury. Schwarzacher SP, Lim TT, Wang B, Kernoff RS, Niebauer J, Cooke JP et al Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation 95 7 — Fulton GJ, Davies MG, Barber L, Gray JL, Svendsen E, Hagen PO Local effects of nitric oxide supplementation and suppression in the development of intimal hyperplasia in experimental vein grafts. Eur J Vasc Endovasc Surg 15 4 — Havelka GE, Moreira ES, Rodriguez MP, Tsihlis ND, Wang Z, Martinez J et al Nitric oxide delivery via a permeable balloon catheter inhibits neointimal growth after arterial injury. J Surg Res 1 — Pearce CG, Najjar SF, Kapadia MR, Murar J, Eng J, Lyle B et al Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radic Biol Med 44 1 — Groves PH, Banning AP, Penny WJ, Newby AC, Cheadle HA, Lewis MJ The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. Cardiovasc Res 30 1 — Harnek J, Zoucas E, Sjuve R, Arner A, Ekblad E, Schou H et al Local infusion of the nitric oxide donor Sin-1 after angioplasty. Effects on intimal hyperplasia in porcine coronary arteries. Acta Radiol 44 4 — Janssens S, Flaherty D, Nong Z, Varenne O, van Pelt N, Haustermans C et al Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 97 13 — Kibbe MR, Tzeng E, Gleixner SL, Watkins SC, Kovesdi I, Lizonova A et al Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg 34 1 — Shears LL 2nd, Kibbe MR, Murdock AD, Billiar TR, Lizonova A, Kovesdi I et al Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 3 — Varenne O, Pislaru S, Gillijns H, Van Pelt N, Gerard RD, Zoldhelyi P et al Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 98 9 — von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M et al Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 92 4 — von der Thusen JH, Fekkes ML, Passier R, van Zonneveld AJ, Mainfroid V, van Berkel TJ et al Adenoviral transfer of endothelial nitric oxide synthase attenuates lesion formation in a novel murine model of postangioplasty restenosis. Arterioscler Thromb Vasc Biol 24 2 — Lei J, Vodovotz Y, Tzeng E, Billiar TR Nitric oxide, a protective molecule in the cardiovascular system. Fishbein I, Guerrero DT, Alferiev IS, Foster JB, Minutolo NG, Chorny M et al Stent-based delivery of adeno-associated viral vectors with sustained vascular transduction and iNOS-mediated inhibition of in-stent restenosis. Gene Ther 24 11 — Rao J, Pan Bei H, Yang Y, Liu Y, Lin H, Zhao X Nitric oxide-producing cardiovascular stent coatings for prevention of thrombosis and restenosis. Front Bioeng Biotechnol. Ali El-Basyuni Y, Li Y, Anand-Srivastava MB Knockdown of Inhibitory guanine nucleotide binding protein gialpha-2 by antisense oligodeoxynucleotides attenuates the development of hypertension and tachycardia in spontaneously hypertensive rats. J Am Heart Assoc 5 Li Y, Anand-Srivastava MB Inactivation of enhanced expression of G i proteins by pertussis toxin attenuates the development of high blood pressure in spontaneously hypertensive rats. Circ Res 91 3 — Sandoval YH, Li Y, Anand-Srivastava MB Transactivation of epidermal growth factor receptor by enhanced levels of endogenous angiotensin II contributes to the overexpression of Gialpha proteins in vascular smooth muscle cells from SHR. Cell Signal 23 11 — Li Y, Sarkar O, Brochu M, Anand-Srivastava MB Natriuretic peptide receptor-C attenuates hypertension in spontaneously hypertensive rats: role of nitroxidative stress and Gi proteins. Hypertension 63 4 — Sarkar O, Li Y, Anand-Srivastava MB Resveratrol prevents the development of high blood pressure in spontaneously hypertensive rats through the inhibition of enhanced expression of Giα proteins. Canadian J Physiol Pharmacol 97 9 — Hermann M, Flammer A, Lüscher TFJTJoCH Nitric oxide in hypertension — Demougeot C, Prigent-Tessier A, Marie C, Berthelot AJJoh Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. Archer SL, Huang JM, Hampl V, Nelson DP, Shultz PJ, Weir EK Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci USA 91 16 — Tanaka Y, Tang G, Takizawa K, Otsuka K, Eghbali M, Song M et al KV channels contribute to nitric oxide-and atrial natriuretic peptide-induced relaxation of a rat conduit artery 1 — Lüscher TF, Spieker LE, Noll G, Cosentino FJJocp Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors S3—S Sandoo A, van Zanten JJCSV, Metsios GS, Carroll D, Kitas GD The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J — Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J et al Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension 23 2 — Lüscher T, Vanhoutte PMJH Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat 8 4 — Panza JA, Quyyumi AA, Brush JE Jr Epstein SEJNEJoM. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension 1 — Nelson RJ, Demas GE, Huang PL, Fishman MC, Dawson VL, Dawson TM et al Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Sun Y, Carretero OA, Xu J, Rhaleb NE, Yang JJ, Pagano PJ et al Deletion of inducible nitric oxide synthase provides cardioprotection in mice with 2-kidney, 1-clip hypertension. Hypertension 53 1 — Friebe A, Koesling D The function of NO-sensitive guanylyl cyclase: what we can learn from genetic mouse models. Nitric Oxide 21 3—4 — Friebe A, Mergia E, Dangel O, Lange A, Koesling D Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc Natl Acad Sci USA 18 — Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C et al Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J 17 11 — Koeppen M, Feil R, Siegl D, Feil S, Hofmann F, Pohl U et al cGMP-dependent protein kinase mediates NO- but not acetylcholine-induced dilations in resistance vessels in vivo. Di Fusco F, Anand-Srivastava MB Nitric oxide synthase inhibition by N omega -nitro-L-arginine methyl ester modulates G-protein expression and adenylyl cyclase activity in rat heart. Am J Hypertens 10 4 Pt 1 — Arnal JF, el Amrani AI, Chatellier G, Menard J, Michel JB Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension 22 3 — Gadkari TV, Cortes N, Madrasi K, Tsoukias NM, Joshi MS Agmatine induced NO dependent rat mesenteric artery relaxation and its impairment in salt-sensitive hypertension. Hypertension 43 5 — Kimura K, Nishio I Impaired endothelium-dependent relaxation in mesenteric arteries of reduced renal mass hypertensive rats. Scand J Clin Lab Invest 59 3 — Stankevicius E, Martinez AC, Mulvany MJ, Simonsen U Blunted acetylcholine relaxation and nitric oxide release in arteries from renal hypertensive rats. J Hypertens 20 8 — Li Q, Youn JY, Cai H Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. J Hypertens 33 6 — Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S et al Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 9 12 — Classen HG, Stein-Hammer C, Thoni H Hypothesis: the effect of oral nitrite on blood pressure in the spontaneously hypertensive rat. Does dietary nitrate mitigate hypertension after conversion to nitrite? J Am Coll Nutr 9 5 — Ling WC, Lau YS, Murugan DD, Vanhoutte PM, Mustafa MR Sodium nitrite causes relaxation of the isolated rat aorta: by stimulating both endothelial NO synthase and activating soluble guanylyl cyclase in vascular smooth muscle. Vascul Pharmacol — Ling WC, Murugan DD, Lau YS, Vanhoutte PM, Mustafa MR Sodium nitrite exerts an antihypertensive effect and improves endothelial function through activation of eNOS in the SHR. Sci Rep Amaral JH, Ferreira GC, Pinheiro LC, Montenegro MF, Tanus-Santos JE Consistent antioxidant and antihypertensive effects of oral sodium nitrite in DOCA-salt hypertension. Redox Biol — Guimaraes DD, Cruz JC, Carvalho-Galvao A, Zhuge Z, Marques SM, Naves LM et al Dietary nitrate reduces blood pressure in rats with angiotensin II-induced hypertension via mechanisms that involve reduction of sympathetic hyperactivity. Hypertension 73 4 — Montenegro MF, Amaral JH, Pinheiro LC, Sakamoto EK, Ferreira GC, Reis RI et al Sodium nitrite downregulates vascular NADPH oxidase and exerts antihypertensive effects in hypertension. Free Radic Biol Med 51 1 — Emdin CA, Khera AV, Klarin D, Natarajan P, Zekavat SM, Nomura A et al Phenotypic consequences of a genetic predisposition to enhanced nitric oxide signaling. Circulation 3 — Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R et al Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23 8 — Cai H, Harrison DG Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87 10 — Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 94 6 — Schlaich MP, Parnell MM, Ahlers BA, Finch S, Marshall T, Zhang WZ et al Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation 24 — Higashi Y, Sasaki S, Nakagawa K, Fukuda Y, Matsuura H, Oshima T et al Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens 15 4 Pt 1 — Hishikawa K, Nakaki T, Suzuki H, Kato R, Saruta T L-arginine as an antihypertensive agent. J Cardiovasc Pharmacol 20 Suppl 12 :S—S J Clin Invest 88 5 — Racasan S, Braam B, van der Giezen DM, Goldschmeding R, Boer P, Koomans HA et al Perinatal L-arginine and antioxidant supplements reduce adult blood pressure in spontaneously hypertensive rats. Hypertension 44 1 — Bagnost T, Ma L, da Silva RF, Rezakhaniha R, Houdayer C, Stergiopulos N et al Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension. Cardiovasc Res 87 3 — Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM et al Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 8 — J Clin Invest 7 — Meininger CJ, Marinos RS, Hatakeyama K, Martinez-Zaguilan R, Rojas JD, Kelly KA et al Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. Biochem J Pt 1 — Heitzer T, Krohn K, Albers S, Meinertz T Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 43 11 — Channon KM Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc Med 14 8 — Maier W, Cosentino F, Lutolf RB, Fleisch M, Seiler C, Hess OM et al Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol 35 2 — Moens AL, Kass DA Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol 26 11 — Katusic ZS Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol 3 :H—H Vallance P, Leone A, Calver A, Collier J, Moncada S Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet — Anderssohn M, Schwedhelm E, Luneburg N, Vasan RS, Boger RH Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diab Vasc Dis Res 7 2 — Das UN, Repossi G, Dain A, Eynard AR L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes. Front Biosci Landmark Ed — J Nutr 10 Suppl S—S. discussion 53S. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS et al Atherosclerosis. Nat Rev Dis Primers 5 1 Steinberg D, Witztum JL Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 30 12 — Glass CK, Witztum JL Atherosclerosis. The road ahead. Cell 4 — Libby P Inflammation in atherosclerosis. Falk E Pathogenesis of atherosclerosis. J Am Coll Cardiol 47 8 Suppl :C Libby P, Bornfeldt KE, Tall AR Atherosclerosis: successes, surprises, and future challenges. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 6 — Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M et al The binding of oxidized low density lipoprotein ox-LDL to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 17 — Aji W, Ravalli S, Szabolcs M, Jiang XC, Sciacca RR, Michler RE et al L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 95 2 — Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 90 3 — Holm P, Korsgaard N, Shalmi M, Andersen HL, Hougaard P, Skouby SO et al Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits. J Clin Invest 4 — Kauser K, da Cunha V, Fitch R, Mallari C, Rubanyi GM Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice. Kubes P, Suzuki M, Granger DN Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88 11 — Alheid U, Frolich JC, Forstermann U Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets. Thromb Res 47 5 — Takahashi M, Ikeda U, Masuyama J, Funayama H, Kano S, Shimada K Nitric oxide attenuates adhesion molecule expression in human endothelial cells. Cytokine 8 11 — Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 76 6 — Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol 22 11 — Download references. Original work contributing to this chapter was supported by grants from the Heart Stroke Foundation of Canada and Canadian Institutes of Health Research to M. and A. Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, C. Centre-Ville, Montreal, QC, H3C 3J7, Canada. You can also search for this author in PubMed Google Scholar. Correspondence to Madhu B. Department of Pharmacology, Hamdard Institute of Medical Sciences and Research, Hamdard University, New Delhi, India. Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India. Reprints and permissions. Li, Y. Nitric Oxide and Cardiovascular Health. In: Ray, A. eds Nitric Oxide: From Research to Therapeutics. Advances in Biochemistry in Health and Disease, vol Springer, Cham. Published : 08 March Publisher Name : Springer, Cham. Print ISBN : Online ISBN : eBook Packages : Biomedical and Life Sciences Biomedical and Life Sciences R0. Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Policies and ethics. Skip to main content. Abstract Nitric oxide NO is a diffusible free radical and universal messenger that is produced from L-arginine by three different isoforms of nitric oxide synthases NOS , neuronal nNOS , inducible iNOS and endothelial NOS eNOS. Keywords Nitric oxide Signaling Nitroxidative stress Vascular remodeling Hypertension Atherosclerosis. Buying options Chapter EUR eBook EUR Softcover Book EUR Hardcover Book EUR Tax calculation will be finalised at checkout Purchases are for personal use only Learn about institutional subscriptions. References Zordoky BN, Robertson IM, Dyck JR Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta 6 — Article CAS PubMed Google Scholar Pokharel S, Sharma UC, Pinto YM Left ventricular hypertrophy: virtuous intentions, malign consequences. Int J Biochem Cell Biol 35 6 — Article CAS PubMed Google Scholar Reaven GM, Laws A Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia 37 9 — Article CAS PubMed Google Scholar Forstermann U, Sessa WC Nitric oxide synthases: regulation and function. Eur Heart J 33 7 —37, 37a—37d Google Scholar Knowles RG, Moncada S Nitric oxide synthases in mammals. Biochem J Pt 2 — Article CAS PubMed PubMed Central Google Scholar Palmer RM, Ashton DS, Moncada S Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature — Article CAS PubMed Google Scholar Li H, Poulos TL Structure-function studies on nitric oxide synthases. J Inorg Biochem 99 1 — Article CAS PubMed Google Scholar Ghafourifar P, Richter C Nitric oxide synthase activity in mitochondria. FEBS Lett 3 — Article CAS PubMed Google Scholar Liu VW, Huang PL Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc Res 77 1 —29 CAS PubMed Google Scholar Merrill JE, Murphy SP, Mitrovic B, Mackenzie-Graham A, Dopp JC, Ding M et al Inducible nitric oxide synthase and nitric oxide production by oligodendrocytes. J Neurosci Res 48 4 — Article CAS PubMed Google Scholar Moncada S, Bolanos JP Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 97 6 — Article CAS PubMed Google Scholar Nathan C Nitric oxide as a secretory product of mammalian cells. FASEB J 6 12 — Article CAS PubMed Google Scholar Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature — Article CAS PubMed Google Scholar Busconi L, Michel T Endothelial nitric oxide synthase. J Biol Chem 12 —3 Google Scholar Marletta MA Nitric oxide synthase: aspects concerning structure and catalysis. Cell 78 6 — Article CAS PubMed Google Scholar Daff S NO synthase: structures and mechanisms. Nitric Oxide 23 1 :1—11 Article CAS PubMed Google Scholar Zhang YH, Casadei B Sub-cellular targeting of constitutive NOS in health and disease. J Mol Cell Cardiol 52 2 — Article CAS PubMed Google Scholar Ignarro LJ Nitric oxide. Hypertension 16 5 —83 Google Scholar Cai S, Khoo J, Mussa S, Alp NJ, Channon KM Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 48 9 — Article CAS PubMed Google Scholar Vallance P, Leiper J Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24 6 — Article CAS PubMed Google Scholar Cosentino F, Katusic ZS Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 91 1 — Article CAS PubMed Google Scholar Kinoshita H, Milstien S, Wambi C, Katusic ZS Inhibition of tetrahydrobiopterin biosynthesis impairs endothelium-dependent relaxations in canine basilar artery. Am J Physiol 2 Pt 2 :H—H CAS PubMed Google Scholar Rodriguez S, Richert L, Berthelot A Increased arginase activity in aorta of mineralocorticoid-salt hypertensive rats. Clin Exp Hypertens 22 1 —85 Article CAS PubMed Google Scholar Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM et al Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 44 6 — Article CAS PubMed Google Scholar Stroes E, Hijmering M, van Zandvoort M, Wever R, Rabelink TJ, van Faassen EE Origin of superoxide production by endothelial nitric oxide synthase. FEBS Lett 3 — Article CAS PubMed Google Scholar Kuzkaya N, Weissmann N, Harrison DG, Dikalov S Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 25 — Article CAS PubMed Google Scholar Pacher P, Beckman JS, Liaudet L Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87 1 — Article CAS PubMed Google Scholar Madiraju P, Hossain E, Anand-Srivastava MB Natriuretic peptide receptor-C activation attenuates angiotensin II-induced enhanced oxidative stress and hyperproliferation of aortic vascular smooth muscle cells. Mol Cell Biochem 1—2 —89 Article CAS PubMed Google Scholar Hossain E, Sarkar O, Li Y, Anand-Srivastava MB Inhibition of overexpression of Gialpha proteins and nitroxidative stress contribute to sodium nitroprusside-induced attenuation of high blood pressure in SHR. Physiol Rep 6 6 :e Article PubMed PubMed Central Google Scholar Balakumar P, Kathuria S, Taneja G, Kalra S, Mahadevan N Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J Mol Cell Cardiol 52 1 —92 Article CAS PubMed Google Scholar Heller R, Munscher-Paulig F, Grabner R, Till U L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem 12 — Article CAS PubMed Google Scholar Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 1 —47 Article CAS PubMed Google Scholar Ignjatovic T, Stanisavljevic S, Brovkovych V, Skidgel RA, Erdos EG Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands. Mol Pharmacol 66 5 — Article CAS PubMed Google Scholar Mason RP, Jacob RF, Kubant R, Jacoby A, Louka F, Corbalan JJ et al Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants. Front Pharmacol Article PubMed PubMed Central Google Scholar Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K et al Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 13 — Article CAS PubMed Google Scholar Wallerath T, Poleo D, Li H, Forstermann U Red wine increases the expression of human endothelial nitric oxide synthase: a mechanism that may contribute to its beneficial cardiovascular effects. J Am Coll Cardiol 41 3 — Article CAS PubMed Google Scholar Wiemer G, Linz W, Hatrik S, Scholkens BA, Malinski T Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. Hypertension 30 5 — Article CAS PubMed Google Scholar Huang A, Vita JA, Venema RC, Keaney JF Jr Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 23 — Article CAS PubMed Google Scholar Griendling KK, Alexander RW Oxidative stress and cardiovascular disease. Circulation 96 10 — CAS PubMed Google Scholar Baradaran A, Nasri H, Rafieian-Kopaei M Oxidative stress and hypertension: possibility of hypertension therapy with antioxidants. J Res Med Sci 19 4 — PubMed PubMed Central Google Scholar Senoner T, Dichtl W Oxidative stress in cardiovascular diseases: still a therapeutic target? Nutrients 11 9 Google Scholar Tsutsui H, Kinugawa S, Matsushima S Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 6 :H—H Article CAS PubMed Google Scholar Montezano AC, Touyz RM Reactive oxygen species and endothelial function—role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin Pharmacol Toxicol 1 —94 Article CAS PubMed Google Scholar Bahnson ES, Koo N, Cantu-Medellin N, Tsui AY, Havelka GE, Vercammen JM et al Nitric oxide inhibits neointimal hyperplasia following vascular injury via differential, cell-specific modulation of SOD-1 in the arterial wall. Nitric Oxide —17 Article CAS PubMed Google Scholar Sarkar O, Li Y, Anand-Srivastava MB Nitric oxide attenuates overexpression of Gialpha proteins in vascular smooth muscle cells from SHR: role of ROS and ROS-mediated signaling. PLoS ONE 12 7 :e Article PubMed PubMed Central Google Scholar Chen Q, Wang Q, Zhu J, Xiao Q, Zhang L Reactive oxygen species: key regulators in vascular health and diseases. Am J Physiol Heart Circ Physiol 5 :H—H Article PubMed Google Scholar Gomez Sandoval YH, Anand-Srivastava MB Enhanced levels of endogenous endothelin-1 contribute to the over expression of Gialpha protein in vascular smooth muscle cells from SHR: role of growth factor receptor activation. Cell Signal 23 2 — Article CAS PubMed Google Scholar Lappas G, Daou GB, Anand-Srivastava MB Oxidative stress contributes to the enhanced expression of Gialpha proteins and adenylyl cyclase signaling in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 23 12 — Article CAS PubMed Google Scholar Hobbs AJ Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol Sci 18 12 — Article CAS PubMed Google Scholar Ignarro LJ, Degnan JN, Baricos WH, Kadowitz PJ, Wolin MS Activation of purified guanylate cyclase by nitric oxide requires heme. Google Scholar Krumenacker JS, Hanafy KA, Murad F Regulation of nitric oxide and soluble guanylyl cyclase. Brain Res Bull 62 6 — Article CAS PubMed Google Scholar Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res 93 10 — Article CAS PubMed Google Scholar Pfeifer A, Ruth P, Dostmann W, Sausbier M, Klatt P, Hofmann F Structure and function of cGMP-dependent protein kinases. Rev Physiol Biochem Pharmacol — Article CAS PubMed Google Scholar Burley DS, Ferdinandy P, Baxter GF Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 6 — Article CAS PubMed PubMed Central Google Scholar Lincoln TM, Wu X, Sellak H, Dey N, Choi CS Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent protein kinase. Front Biosci — Article CAS PubMed Google Scholar Wang S, Li Y Expression of constitutively active cGMP-dependent protein kinase inhibits glucose-induced vascular smooth muscle cell proliferation. Am J Physiol Heart Circ Physiol 6 :H—H Article CAS PubMed Google Scholar Fukao M, Mason HS, Britton FC, Kenyon JL, Horowitz B, Keef KD Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine J Biol Chem 16 — Article CAS PubMed Google Scholar Jahn H, Nastainczyk W, Rohrkasten A, Schneider T, Hofmann F Site-specific phosphorylation of the purified receptor for calcium-channel blockers by cAMP- and cGMP-dependent protein kinases, protein kinase C, calmodulin-dependent protein kinase II and casein kinase II. Eur J Biochem 2 — Article CAS PubMed Google Scholar Layland J, Li JM, Shah AM Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes. J Physiol Pt 2 — Article CAS PubMed PubMed Central Google Scholar Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S et al Guanylyl cyclases and signaling by cyclic GMP. Mol Cell Biol 18 12 — Article CAS PubMed PubMed Central Google Scholar Bassil M, Anand-Srivastava MB Nitric oxide modulates Gi-protein expression and adenylyl cyclase signaling in vascular smooth muscle cells. Free Radic Biol Med 41 7 — Article CAS PubMed Google Scholar Kibbe MR, Nie S, Seol DW, Kovesdi I, Lizonova A, Makaroun M et al Nitric oxide prevents p21 degradation with the ubiquitin-proteasome pathway in vascular smooth muscle cells. J Vasc Res 41 3 — Article CAS PubMed Google Scholar Arejian M, Li Y, Anand-Srivastava MB Nitric oxide attenuates the expression of natriuretic peptide receptor C and associated adenylyl cyclase signaling in aortic vascular smooth muscle cells: role of MAPK. Am J Physiol Heart Circ Physiol 6 :H—H Article CAS PubMed Google Scholar Bian K, Ke Y, Kamisaki Y, Murad F Proteomic modification by nitric oxide. J Pharmacol Sci 4 — Article CAS PubMed Google Scholar Cornwell TL, Arnold E, Boerth NJ, Lincoln TM Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 5 Pt 1 :C—C Article CAS PubMed Google Scholar Lima B, Forrester MT, Hess DT, Stamler JS S-nitrosylation in cardiovascular signaling. Circ Res 4 — Article CAS PubMed PubMed Central Google Scholar Schulman IH, Hare JM Regulation of cardiovascular cellular processes by S-nitrosylation. Biochim Biophys Acta 6 — Article CAS PubMed Google Scholar Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA et al S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature — Article CAS PubMed PubMed Central Google Scholar Jia M, Mateoiu C, Souchelnytskyi S Protein tyrosine nitration in the cell cycle. Biochem Biophys Res Commun 2 — Article CAS PubMed Google Scholar Batista WL, Ogata FT, Curcio MF, Miguel RB, Arai RJ, Matsuo AL et al S-nitrosoglutathione and endothelial nitric oxide synthase-derived nitric oxide regulate compartmentalized ras S-nitrosylation and stimulate cell proliferation. Antioxid Redox Signal 18 3 — Article CAS PubMed Google Scholar Gow AJ, Duran D, Malcolm S, Ischiropoulos H Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation. FEBS Lett 1—2 —66 Article CAS PubMed Google Scholar Hellberg CB, Boggs SE, Lapetina EG Phosphatidylinositol 3-kinase is a target for protein tyrosine nitration. Biochem Biophys Res Commun 2 — Article CAS PubMed Google Scholar Sun J, Steenbergen C, Murphy E S-nitrosylation: NO-related redox signaling to protect against oxidative stress. Antioxid Redox Signal 8 9—10 — Article CAS PubMed Google Scholar Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature — Article CAS PubMed Google Scholar Hadrava V, Kruppa U, Russo RC, Lacourciere Y, Tremblay J, Hamet P Vascular smooth muscle cell proliferation and its therapeutic modulation in hypertension. Am Heart J 4 Pt 2 — Article CAS PubMed Google Scholar Intengan HD, Schiffrin EL Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 38 3 Pt 2 — Article CAS PubMed Google Scholar Touyz RM Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 90 4 — Article CAS PubMed Google Scholar Intengan HD, Deng LY, Li JS, Schiffrin EL Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension 33 1 Pt 2 — Article CAS PubMed Google Scholar Ross R, Glomset J, Kariya B, Harker L A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro 71 4 — Google Scholar Raines EWJ PDGF and cardiovascular disease 15 4 — CAS Google Scholar Inagami T, Eguchi S Angiotensin II-mediated vascular smooth muscle cell growth signaling 33 6 — Google Scholar Li Y, Lévesque L-O, Anand-Srivastava MB Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyper proliferation of vascular smooth muscle cells of SHR. Am J Physiol Heart Circ Physiol 5 :H—H Article PubMed Google Scholar Gomez Y-H, Anand-Srivastava M Enhanced levels of endogenous endothelin-1 contribute to the over expression of Giα protein in vascular smooth muscle cells from SHR: role of growth factor receptor activation. Am J Physiol Heart Circ Physiol 6 :H—H Article CAS PubMed Google Scholar Gomez Sandoval YH, Levesque LO, Anand-Srivastava MB Contribution of epidermal growth factor receptor transactivation in angiotensin II-induced enhanced expression of Gi protein and proliferation in A10 vascular smooth muscle cells. Can J Physiol Pharmacol 87 12 — Article CAS PubMed Google Scholar Gomez Sandoval YH, Levesque LO, Li Y, Anand-Srivastava MB Role of epidermal growth factor receptor transactivation in endothelininduced enhanced expression of Gi protein and proliferation in A10 vascular smooth muscle cells. Can J Physiol Pharmacol 91 3 — Article CAS PubMed Google Scholar Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H et al Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 25 9 — Article CAS PubMed Google Scholar Atef ME, Anand-Srivastava MB Enhanced expression of Gqalpha and PLC-beta1 proteins contributes to vascular smooth muscle cell hypertrophy in SHR: role of endogenous angiotensin II and endothelin Am J Physiol Cell Physiol 1 :C Article CAS PubMed Google Scholar Hahn AW, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Buhler FR Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul 1 9 — Article CAS PubMed PubMed Central Google Scholar Kanse SM, Takahashi K, Warren JB, Perera T, Porta M, Ghatei M et al Production of endothelin by vascular smooth muscle cells. J Cardiovasc Pharmacol 17 Suppl 7 :S—S Article CAS PubMed Google Scholar Kubo A, Fukuda N, Soma M, Izumi Y, Kanmatsuse K Inhibitory effect of an angiotensin II type 1 receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 27 1 —63 Article CAS PubMed Google Scholar Lu MH, Chao CF, Tsai SH, Chen JY, Chang LT Autocrine effects of endothelin on in vitro proliferation of vascular smooth muscle cells from spontaneously hypertensive and normotensive rats. Clin Exp Hypertens 28 5 — Article CAS PubMed Google Scholar Hadrava V, Tremblay J, Hamet P Abnormalities in growth characteristics of aortic smooth muscle cells in spontaneously hypertensive rats. Hypertension 13 6 Pt 1 — Article CAS PubMed Google Scholar Tanner FC, Greutert H, Barandier C, Frischknecht K, Luscher TF Different cell cycle regulation of vascular smooth muscle in genetic hypertension. Hypertension 42 2 — Article CAS PubMed Google Scholar Bou Daou G, Li Y, Anand-Srivastava MB Enhanced expression of Gialpha proteins contributes to the hyperproliferation of vascular smooth muscle cells from spontaneously hypertensive rats via MAP kinase- and PI3 kinase-independent pathways. PLoS ONE 8 10 :e Article PubMed PubMed Central Google Scholar Li Y, Levesque LO, Anand-Srivastava MB Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am J Physiol Heart Circ Physiol 6 :H—H Article CAS PubMed Google Scholar Rahali S, Li Y, Anand-Srivastava MB Contribution of oxidative stress and growth factor receptor transactivation in natriuretic peptide receptor C-mediated attenuation of hyperproliferation of vascular smooth muscle cells from SHR. PLoS ONE 13 1 :e Article PubMed PubMed Central Google Scholar Saito S, Frank GD, Mifune M, Ohba M, Utsunomiya H, Motley ED et al Ligand-independent trans-activation of the platelet-derived growth factor receptor by reactive oxygen species requires protein kinase C-delta and c-Src. J Biol Chem 47 — Article CAS PubMed Google Scholar Dubey RK Vasodilator-derived nitric oxide inhibits fetal calf serum- and angiotensin-II-induced growth of renal arteriolar smooth muscle cells. J Pharmacol Exp Ther 1 — CAS PubMed Google Scholar Dubey RK, Jackson EK, Luscher TF Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. J Clin Invest 96 1 —9 Google Scholar Garg UC, Hassid A Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83 5 — Article CAS PubMed PubMed Central Google Scholar Tsihlis ND, Oustwani CS, Vavra AK, Jiang Q, Keefer LK, Kibbe MR Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH Cell Biochem Biophys 60 1—2 —97 Article CAS PubMed PubMed Central Google Scholar Bahnson ES, Kassam HA, Moyer TJ, Jiang W, Morgan CE, Vercammen JM et al Targeted nitric oxide delivery by supramolecular nanofibers for the prevention of restenosis after arterial injury. Arterioscler Thromb Vasc Biol 29 2 — Article CAS PubMed Google Scholar Sharma RV, Tan E, Fang S, Gurjar MV, Bhalla RC NOS gene transfer inhibits expression of cell cycle regulatory molecules in vascular smooth muscle cells. Am J Physiol 5 :H—H CAS PubMed Google Scholar Tanner FC, Meier P, Greutert H, Champion C, Nabel EG, Luscher TF Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Can J Physiol Pharmacol 98 1 —43 Article CAS PubMed Google Scholar Yu SM, Hung LM, Lin CC cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Am J Physiol Heart Circ Physiol 4 :H—H Article CAS PubMed Google Scholar Lehners M, Dobrowinski H, Feil S, Feil R. Google Scholar Segura-Puimedon M, Mergia E, Al-Hasani J, Aherrahrou R, Stoelting S, Kremer F et al Proatherosclerotic effect of the alpha1-subunit of soluble guanylyl cyclase by promoting smooth muscle phenotypic switching. Am J Pathol 8 — Article CAS PubMed Google Scholar Maruhashi T, Noma K, Iwamoto Y, Iwamoto A, Oda N, Kajikawa M et al Critical role of exogenous nitric oxide in ROCK activity in vascular smooth muscle cells. PLoS ONE 9 10 :e Article PubMed PubMed Central Google Scholar Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 78 2 — Article CAS PubMed Google Scholar Gurjar MV, Sharma RV, Bhalla RC eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol 19 12 — Article CAS PubMed Google Scholar Largiader T, Eto M, Payeli SK, Greutert H, Viswambharan H, Lachat M et al Endothelial nitric oxide synthase gene transfer inhibits human smooth muscle cell migration via inhibition of Rho A. J Cardiovasc Pharmacol 52 4 — Article CAS PubMed Google Scholar McNamara DB, Bedi B, Aurora H, Tena L, Ignarro LJ, Kadowitz PJ et al L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun 1 — Article CAS PubMed Google Scholar Taguchi J, Abe J, Okazaki H, Takuwa Y, Kurokawa K L-arginine inhibits neointimal formation following balloon injury. Life Sci 53 23 :PL—PL Google Scholar Guo JP, Panday MM, Consigny PM, Lefer AM Mechanisms of vascular preservation by a novel NO donor following rat carotid artery intimal injury. Am J Physiol 3 Pt 2 :H—H CAS PubMed Google Scholar Kaul S, Cercek B, Rengstrom J, Xu XP, Molloy MD, Dimayuga P et al Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB. J Am Coll Cardiol 35 2 — Article CAS PubMed Google Scholar Lee JS, Adrie C, Jacob HJ, Roberts JD Jr, Zapol WM, Bloch KD Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury. Circ Res 78 2 — Article CAS PubMed Google Scholar Schwarzacher SP, Lim TT, Wang B, Kernoff RS, Niebauer J, Cooke JP et al Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation 95 7 — Article CAS PubMed Google Scholar Fulton GJ, Davies MG, Barber L, Gray JL, Svendsen E, Hagen PO Local effects of nitric oxide supplementation and suppression in the development of intimal hyperplasia in experimental vein grafts. Eur J Vasc Endovasc Surg 15 4 — Article CAS PubMed Google Scholar Havelka GE, Moreira ES, Rodriguez MP, Tsihlis ND, Wang Z, Martinez J et al Nitric oxide delivery via a permeable balloon catheter inhibits neointimal growth after arterial injury. J Surg Res 1 —42 Article CAS PubMed Google Scholar Pearce CG, Najjar SF, Kapadia MR, Murar J, Eng J, Lyle B et al Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. |
| What is Nitric Oxide's Role in the Body? | Huang A, Antiviral health supplements Hearh, Venema RC, Keaney JF Amino acid neurotransmitters Ascorbic acid enhances endothelial nitric-oxide synthase activity by healtu intracellular tetrahydrobiopterin. Leung W-H, Lau C-P, Wong C-K. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. Serrano, N. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. |
| Study finds nitric oxide may also determine drug efficacy | Circulating nitrite hesrt to cardioprotection Nitruc remote ischemic healfh. Boosts exercise performance. Lancet — Article CAS Antiviral health supplements Google Scholar Anderssohn Nitric oxide and heart health, Hert E, Prediabetes physical activity N, Vasan RS, Boger RH Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Anyone you share the following link with will be able to read this content:. Schleifenbaum, J. Google Scholar. Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. |
Nitric Antiviral health supplements NO is Meal planning for food allergies diffusible helth radical and universal messenger that is produced from L-arginine by three different isoforms of nitric oxide synthases NOSneuronal nNOSinducible iNOS and endothelial NOS Nitric oxide and heart health. NO Nitric oxide and heart health ozide important role in the regulation of heaet of oide functions including myocardial contractility, vascular tone, hfalth pressure, Enhancing endurance performance growth, proliferation and platelet aggregation. Most of the effects of NO are mediated through the activation of soluble guanylate cyclase—cGMP system, however, cGMP-independent pathways have also been shown to be responsible in mediating its effects. The levels of NO are regulated by several factors and cofactors required for the activation of NOS, however, reduced bioavailability of these factors results in the decreased levels of NO and thereby endothelial dysfunction leading to the pathogenesis of cardiovascular diseases including hypertension, diabetes, atherosclerosis etc. This review will focus on the role of NO in physiology and pathophysiology of cardiovascular system including vascular remodeling, hypertension and the underlying molecular mechanisms contributing to these functions. Nitric oxide and heart health -
They share homology in regions involved in cofactor binding for example, FAD, FMN, and NADPH ribose and adenine binding sites , and have similar enzymatic mechanisms that involve electron transfer for oxidation of the terminal guanidino nitrogen of l -arginine.
However, their expression patterns differ, as do the detailed regulations of their activity. nNOS is predominantly expressed in certain neurons and in skeletal muscle, whereas eNOS is predominantly expressed in endothelial cells. Despite their names, a variety of cell types express these isoforms, with many tissues expressing more than one isoform.
Furthermore, the innervation and vasculature in all tissues have the potential to express nNOS and eNOS, while circulating blood elements may express iNOS.
In contrast, iNOS expression is induced in activated macrophages as an immune response. For enzymatic activity, NOS proteins must bind cofactors and dimerize. The additions of l -arginine, BH 4 and heme allow the NOS protein to form dimers. eNOS and nNOS dimers formed this way are inactive, and depend on calmodulin binding stimulated by increases in intracellular calcium.
Thus, the main switch for activity for nNOS and eNOS is a transient increase in intracellular calcium concentration, whereas the main switch for iNOS is at the level of transcription.
Each isoform has notable structural features. The nNOS gene encodes a PDZ domain in exon 2 that is required for membrane association. eNOS is also regulated by phosphorylation at multiple sites, including serine and threonine In addition to nNOS, eNOS, and iNOS, there is a constitutively active NOS isoform present in mitochondria, referred to as mtNOS.
However, whether mtNOS corresponds to one of the three known isoforms is not known. In many cells and for many of the biological signaling roles of NO, the physiologic target is soluble guanylate cyclase.
This is responsible for events in the brain following NMDA receptor activation. Garthwaite first described that cultures of cerebellar cells produce cGMP in response to the excitatory amino acid neurotransmitter glutamate.
Similarly, NO produced as a neurotransmitter in the autonomic nervous system innervating the gastrointestinal tract, urinary tract, and the respiratory tract, mediates smooth muscle relaxation in these tissues by increases in cGMP production.
These effects are likely mediated by the phosphorylation of downstream proteins by cGMP-dependent protein kinases, including myosin light chain. Another target for NO is sulfhydryl groups on proteins, to form nitrosothiol compounds.
In addition to NO, NOS enzymes are capable of generating reactive oxygen species. Under conditions of limited l -arginine bioavailability, eNOS may generate H 2 O 2. NOS enzymes can be inhibited by pharmacologic agents, including arginine analogs substituted at the terminal guanidino nitrogens.
These arginine analogs bind to NOS, but cannot serve as substrate, so they compete with l -arginine and inhibit the enzyme. Such pharmacologic NOS inhibitors have yielded a tremendous amount of valuable information.
Indeed, blockade of a biological process by l -nitro-arginine L-NA or l - N -arginine-methyl-ester L-NAME , and outcompetition of this effect by an excess of l -arginine, provides very strong evidence for the involvement of NO in that process.
One potential limitation of pharmacologic inhibitors, however, is that they may inhibit more than one NOS isoform. There are also structurally distinct inhibitors of NOS that are not arginine analogs e.
A complementary approach is to manipulate the genes that encode the NOS enzymes to generate knockout mice in which a particular NOS gene has been disrupted. This approach complements pharmacologic approaches because its specificity is at the genetic level.
It pinpoints the roles of individual NOS genes, since many tissues contain all three of the major NOS isoforms. Further, it allows the study of how chronic absence of the NOS isoform affects physiology in intact animals. Table 2 shows some of the functions of the NOS isoforms, and the phenotypes of NOS knockout mice.
Several issues unique to the genetic approach should be kept in mind, as they can potentially confound studies using knockout animals. First, there may be developmental abnormalities due to the gene knockout. If one of the NOS isoforms plays a critical role in embryonic development, its absence may lead to other secondary abnormalities that are difficult to predict.
Second, additional phenotypes may emerge from changes to pathways that act upstream or downstream to the gene product of interest. Third, other isoforms or gene products, acting in parallel, may compensate for the absent gene product and mask possible phenotypes.
Finally, embryonic stem cells used to generate knockout mice are often derived from particular strains like the SV strain that are better sources of pluripotent embryonic stem cells. These knockout mice have mixed genetic background, which may itself lead to phenotypic abnormalities.
The first line of nNOS knockout mice was established by disrupting exon 2 of nNOS using homologous recombination. They have significantly diminished NO production in the brain, as measured by NOS enzymatic assay, cGMP levels, and measurement of NO by spin trapping.
These splice variants are soluble, since they lack the PDZ domain. The most apparent phenotype of nNOS knockout mice is enlargement of the stomachs, often to several times the normal size, demonstrating a role for nNOS in smooth muscle relaxation of the pyloric sphincter.
nNOS knockout mice are also resistant to focal and global cerebral ischaemia, consistent with a role for nNOS-derived NO in cellular injury following ischaemia.
The first eNOS knockout mice were generated by disrupting the region that encodes for the NADPH ribose and adenine binding sites, which are essential for catalytic activity.
As outlined below, eNOS knockout mice show abnormalities in vascular relaxation, blood pressure regulation, and cardiac contractility. They are a useful animal model for endothelial dysfunction, as they show increased propensity to form neointima in response to vessel injury, 53 , 54 and accelerated and more severe diet-induced atherosclerosis in the apolipoprotein E apoE knockout mouse model.
Several additional strains of eNOS knockout mice have also been reported. In one strain, the eNOS gene was disrupted at the calmodulin binding site, encoded by exons 12 and 13, 57 In another strain, the NADPH ribose and adenine binding sites were disrupted, 58 similar to the first eNOS knockout mice.
The fact that independently generated mice, particularly those in which different parts of the eNOS gene were targeted, have similar phenotypes, adds confidence that the observed phenotypes are specific.
Three separate groups independently disrupted the iNOS gene. MacMicking et al. deleted the promoter region and the first four exons, including the initiation codon ATG.
in an attempt to delete the first five exons of the gene, created a genomic rearrangement of the iNOS gene that results in an aberrant transcript, but no detectable iNOS activity. disrupted the calmodulin, FAD, and FMN binding domains of iNOS, and found no detectable iNOS mRNA or protein.
Peritoneal macrophages from all of the iNOS mutant mice are deficient in NO and nitrite production. None of the mutants demonstrate abnormalities in growth, fertility, or gross histopathology. Initial characterization of these iNOS mutant animals centered on two proposed functions of iNOS: cell-mediated resistance to pathogens, and hemodynamic responses to septic shock.
Inducible NOS mutant mice are more sensitive to the intracellular pathogen Listeria monocytogenes 59 and to the intracellular protozoan parasite Leishmania major 60 than are wild-type mice.
Both are pathogens that elicit cell-mediated immune responses, and the increased susceptibility of iNOS mutant mice demonstrates the importance of iNOS to host defenses against these pathogens.
The role of iNOS in septic shock is supported by the finding that NO is produced in large quantities during infection. Multiple studies show that NOS inhibitors can reverse the hypotension of patients in septic shock, 63 , 64 or of animals treated with LPS or TNF.
In , Furchgott and Zawadzki found that acetylcholine is able to cause relaxation of blood vessels if, and only if, the endothelium is intact. This indicated that acetylcholine does not act directly on vascular smooth muscle, but rather, that the endothelium plays a key role in vasodilation.
This led to the proposal of the existence of endothelium-derived relaxing factor, or EDRF. One of the first experiments in eNOS knockout mice was to replicate the experiments of Furchgott and Zawadzki. In fact, isolated aortic rings from eNOS knockout do not respond to acetylcholine in organ baths.
These observations establish that eNOS is an essential source of NO in the vasculature, and it is required for EDRF activity. There are several interacting homeostatic regulators of blood pressure, including the renin—angiotensin system, the autonomic nervous system, and local mediators such as EDRF.
L-NA and other NOS inhibitors cause a rise in blood pressure in many species, including rats, guinea pigs, rabbits, dogs and mice. Therefore, it was of particular interest to examine basal blood pressure in the eNOS mutant mice to see if other homeostatic mechanisms would compensate for the absence of endothelial NO production.
This is true regardless of the types of anesthesia used and in the awake state , and is also true for independently generated eNOS knockout mouse strains. Thus, eNOS plays a key role in regulation of blood pressure. However, it is not clear why other homeostatic systems cannot compensate for absence of eNOS.
The set point for systemic blood pressure is regulated through integration of cardiac, neuronal, humoral and vascular mechanisms. One possibility is that the renin—angiotensin system and autonomic nervous system evolved to serve primarily as a defense against hypotension, and diminution in their activity is a poor buffer against hypertension.
Alternatively, eNOS and indeed other NOS isoforms may be involved in establishing the baroreceptor set point. eNOS mutant mice show a decrease in blood pressure in response to L-NA.
This hypotensive effect of L-NA is prevented by l -arginine and is not observed with d -nitro-arginine. This suggests that non-endothelial NOS isoforms may play a direct or indirect role in the maintenance of blood pressure. nNOS knockout mice, whose blood pressure values are similar to wild-type littermates when awake, tend to be hypotensive under anesthesia.
nNOS is present in central vasomotor centers, perivascular nerves, and skeletal muscle, and its effects in these locations may counter the direct vasodilatory effect of NO in vessels.
Multiple roles for endothelial and non-endothelial NOS isoforms in vasodilation and vasoconstriction could also explain the observed variability in maximal pressor effects of various NOS inhibitors.
NO is critical to the pathophysiology of vascular disease and the concept of endothelial dysfunction. Endothelial dysfunction is defined as impairment of physiologic endothelium-dependent relaxation.
It occurs in atherosclerosis, hypertension, diabetes, hypercholesterolemia, and normal aging. This is therefore an early event in the pathophysiology of atherosclerosis. Clinically, endothelial function can be tested by using ultrasound to determine the forearm blood flow response to reflow hyperemia.
Experimentally, endothelial function can be tested by using a myograph to determine the vasodilator response of an isolated vessel segment to pharmacologic agents such as acetylcholine, bradykinin, and VEGF. Endothelial dysfunction is characterized by diminished endothelial NO levels. Because eNOS knockout mice completely lack endothelial NO production, they serve as a model of extreme endothelial dysfunction.
There are several potential mechanisms for endothelial dysfunction, as outlined in Figure 1. First, changes in eNOS mRNA or protein expression levels can lead to a reduction in eNOS activity. Second, l -arginine, the substrate for NO production, can be limiting in tissues. An endogenous competitive inhibitor, asymmetric dimethylarginine ADMA may reduce endothelial NO production even in the presence of adequate l -arginine levels.
Regulation of eNOS activity and mechanisms for endothelial dysfunction. ADMA, asymmetric dimethylarginine; SOD, superoxide dismutase; PKG, protein kinase G.
While eNOS plays important roles in vessel function, excessive NO production may contribute to the development of atherosclerosis. iNOS is expressed in activated monocytes and macrophages, and both iNOS and nNOS are expressed in vascular smooth muscle cells in atherosclerotic lesions.
NO and peroxynitrite can both increase oxidative stress and oxidize LDL. NO can also affect redox-sensitive transcription of genes involved in endothelial cell activation such as VCAM Atherosclerosis is driven by biochemical, cellular, and hemodynamic forces in the vessel wall that cause vascular injury, ultimately leading to endothelial dysfunction, cellular proliferation, recruitment of inflammatory cells, and accumulation of oxidized LDL.
Vascular smooth muscle cells proliferate in the medial layer and migrate across the internal elastic lamina to form the neointima.
NO suppresses smooth muscle proliferation in response to vessel injury, 91 suggesting that it normally serves a protective role. In association with other effects such as inhibition of platelet aggregation and adhesion 2 and inhibition of leukocyte activation and adhesion, 5 , 92 NO normally suppresses the processes that lead to the development of atherosclerotic plaques.
A relative deficiency in vascular NO would reduce these normally protective effects and thereby predispose to atherosclerosis. To assess whether eNOS has a role in neointima formation following vascular injury, eNOS knockout mice were subjected to a cuff model of vascular injury.
Thus, results from eNOS knockout mice confirm results using pharmacologic agents, and show that a deficiency in the amount of available NO in the vessel wall by itself increases neointimal formation in response to vascular injury.
To mimic human diet-induced atherosclerosis, apoE knockout mice have been a useful mouse model. It is also the first murine model to demonstrate spontaneous distal coronary arteriosclerosis associated with left ventricular dysfunction.
These findings support the concept that restoration of eNOS function in patients with atherosclerosis is an important therapeutic goal. The reduction in atherosclerosis in double knockout animals is associated with decreased plasma levels of lipoperoxides, suggesting that reduction in iNOS-mediated oxidative stress may explain the protection from lesion formation in double knockout animals.
Thus, genetic deficiency of iNOS decreases atherosclerosis in Western diet-fed apoE knockout animals. nNOS deficiency significantly reduces the mean arterial blood pressure in female apoE knockout mice but is unchanged in male mice.
Thus, there is evidence that nNOS may serve atheroprotective roles, like eNOS. Following cerebral ischaemia, NO levels in the brain rise several orders of magnitude, from baseline nanomolar levels to stimulated micromolar levels. These results confirm that although it normally serves important vascular physiological roles, NO overproduction in the setting of cerebral ischaemia actually contributes to tissue damage.
Measurements of regional cerebral blood flow rCBF by laser Doppler flowmetry show that both nNOS knockout mice and wild-type mice have similar reductions in blood flow. Thus, the smaller infarct sizes in the nNOS knockout mice cannot be explained by differences in cerebral blood flow. Like nNOS, iNOS contributes to tissue damage after cerebral ischaemia.
Inhibition of iNOS by selective pharmacologic inhibitors, or gene deletion of iNOS, reduces this late damage. In contrast, eNOS knockout mice subjected to the MCA occlusion model develop larger infarct sizes compared to wild-type mice.
This confirms that eNOS normally serves to vasodilate and preserve blood flow in the setting of ischaemia; in its absence, inability to preserve blood flow contributes to the enlarged infarct sizes observed in eNOS knockout mice. Ischaemic preconditioning IPC refers to processes by which brief, sublethal episodes of ischaemia stimulate a protective response against subsequent, more severe, ischaemia.
Although there are similarities between different tissues, it is not known whether the triggers and mediators of IPC are the same in all tissues. The potential protective mechanisms include alterations in cell death genes, heat shock proteins, lipid peroxidation, inflammation, and mitochondrial metabolism.
Rapid IPC occurs when the preconditioning stimulus precedes the severe ischaemic insult by a short time interval minutes to several hours , while delayed IPC occurs requires a longer time interval hours to days to develop.
It has been hypothesized that delayed IPC may involve changes in gene expression and new protein synthesis. Pharmacologic studies suggest separable roles for each of the NOS isoforms in cerebral IPC. In a newborn rat model of hypoxia-ischaemia, preconditioning by mild hypoxia protects against more severe hypoxia 24 h later.
In another rat model, both transient cerebral ischaemia and LPS could protect against later ischaemia. The anesthetics isoflurane and halothane also protect against cerebral ischaemia 24 h later.
Cerebral IPC is more difficult to study in mice for technical reasons because the vessels are smaller. However, a mouse model of rapid preconditioning has been developed.
Infarct size measured 24 h later is reduced in preconditioned animals. This mouse model allows the study of NOS knockout mice to determine the separate roles of NOS isoforms. While wild-type mice demonstrate a reduction in infarct size following 3 cycles of IPC, neither eNOS knockout mice nor nNOS knockout mice do.
Relative blood flow measurements by laser Doppler flowmetry confirm effective MCA occlusion with each preconditioning episode in each of the three genotypes. These results suggest that both nNOS and eNOS are required for cerebral IPC. There are several potential mechanisms by which NO mediates IPC.
Second, NO may be involved as a mediator of protection by affecting neuronal resistance to ischaemic phenomena. Third, as a vasodilator, NO may augment blood flow by vasodilation, reducing leukocyte-endothelial interactions and platelet-endothelial interactions.
Together these effects would limit the functional effect of ischaemia. In the heart, NO is thought to play important protective roles, not only through blood flow effects, but also by directly enhancing cardioprotection.
Myocardial ischaemia-reperfusion injury, and cardiac IPC appear to depend on iNOS, rather than nNOS or eNOS. iNOS knockout animals may be useful tools to define these processes. Pharmacologic blockade of NOS activity first suggested that NO plays a significant role in regulating cardiac contractility.
Endothelial cells are rich in eNOS and line the vasculature and endocardium. Cardiac myocytes, which are essential for cardiac excitation-contraction coupling, express both eNOS and nNOS.
In cardiac myocytes, eNOS is localized to the sarcolemmal caveolae through its interaction with caveolin eNOS and nNOS in cardiac excitation—contraction coupling.
In cardiac myocytes, eNOS associates with caveolin-3 at the sarcolemma, where it blunts inotropic response to isoproterenol stimulation. Using Langendorff isolated heart preparations and in vivo measurements, Gyurko et al.
found that eNOS knockout mice show no difference in basal contractility, but they do show enhanced inotropic and lusitropic responses to isoproterenol stimulation.
nNOS knockout mice have been studied for phenotypes related to cardiac contractility, with variable results.
In one case, nNOS knockout mice, as well as pharmacologic inhibition of nNOS in wild-type mice, causes enhanced basal LV contraction. The subcellular localization of nNOS to the sarcoplasmic reticulum suggests that NO can modulate cardiomyocyte calcium handling.
There is direct evidence that nNOS nitrosylates and activates the ryanodine receptor. Thus, nNOS normally maintains function of the ryanodine receptor, and in its absence, contractility will be affected. In patients with congestive heart failure, there is also evidence that nNOS is not properly localized to the sarcoplasmic reticulum.
The importance of nNOS to cardiac contractility and calcium handling is underscored by the recent finding that long QT syndrome, associated with dangerous ventricular arrhythmias in humans, is closely associated with NOS1-activating protein NOS1AP , which binds to nNOS.
In addition to the cardiovascular phenotypes discussed here, mutant mice have been useful to define the roles of each NOS isoform in other biological processes.
Targeted disruption of the nNOS, iNOS and eNOS genes in mice has led to the development of mutant mice that have been useful tools with which to study how NO affects blood pressure regulation, endothelial dysfunction, response to vascular injury, response to stroke and cerebral ischaemia, diet-induced atherosclerosis and cardiac contractility.
As we begin to understand better the many diverse roles of NO, we can build upon this foundation to translate these findings into novel clinical approaches to prevent and treat cardiovascular diseases.
Because patients with cardiovascular diseases are not totally devoid of either nNOS or eNOS, future work will likely involve more refined approaches to modulate the activity of NOS isoforms short of total gene disruption.
Candidate regulatory sites and domains can be mutated, and the effects of these modifications can be studied in vivo. Perspectives from biochemistry, molecular biology, cell biology, physiology, chemistry and pharmacology will all complement genetic approaches to studying the roles of NO in cardiovascular diseases.
This work was supported by National Institutes of Health R01 grants NS, NS, and HL to PLH. Google Scholar. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.
Sign In or Create an Account. Advertisement intended for healthcare professionals. Navbar Search Filter Cardiovascular Research This issue ESC Publications Cardiovascular Medicine Books Journals Oxford Academic Mobile Enter search term Search.
ESC Publications. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents Abstract. Nitric oxide synthases. Molecular targets of NO. Genetic approaches. nNOS knockout mice. eNOS knockout mice.
iNOS knockout mice. Endothelium-derived relaxing factor activity. Blood pressure. Reduced bioavailability of NO is thought to be one of the central factors common to cardiovascular disease, although it is unclear whether this is a cause of, or result of, endothelial dysfunction.
Disturbances in NO bioavailability leads to a loss of the cardio protective actions and in some case may even increase disease progression. In this chapter the cellular and biochemical mechanisms leading to reduced NO bioavailability are discussed and evidence for the prevalence of these mechanisms in cardiovascular disease evaluated.
Abstract Nitric oxide NO is a gaseous lipophilic free radical cellular messenger generated by three distinct isoforms of nitric oxide synthases NOS , neuronal nNOS , inducible iNOS and endothelial NOS eNOS.
Publication types Review.
Nitric oxide NO is a gaseous lipophilic free radical cellular messenger generated by three distinct isoforms of nitric Nitric oxide and heart health Nitricc NOSneuronal oxidsinducible iNOS and Organic salad greens Antiviral health supplements eNOS. NO plays Nirtic important Niric in the protection against the onset and progression of oxire disease. Cardiovascular disease kxide Antiviral health supplements with a number of different disorders including hypercholesterolaemia, hypertension and diabetes. The underlying pathology for most cardiovascular diseases is atherosclerosis, which is in turn associated with endothelial dysfunctional. The cardioprotective roles of NO include regulation of blood pressure and vascular tone, inhibition of platelet aggregation and leukocyte adhesion, and prevention smooth muscle cell proliferation. Reduced bioavailability of NO is thought to be one of the central factors common to cardiovascular disease, although it is unclear whether this is a cause of, or result of, endothelial dysfunction. Disturbances in NO bioavailability leads to a loss of the cardio protective actions and in some case may even increase disease progression.
Wacker, Ihr Gedanke ist sehr gut